8-K: Spruce Biosciences Gains Nasdaq Reprieve, Must Regain Compliance by August 5th

Spruce Biosciences, Inc. announced that its appeal against Nasdaq delisting was accepted, allowing the company to resume trading on the Nasdaq Capital Market if it regains compliance with the minimum bid price requirement by August 5, 2025.

Summary

• Spruce Biosciences, Inc. (SPRB) received a delisting notice from Nasdaq on April 22, 2025, due to its failure to comply with the minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)).
• The company's common stock was suspended from trading on the Nasdaq Capital Market on April 29, 2025, and subsequently began trading on the OTC Pink Marketplace under the symbol SPRB.
• Spruce Biosciences appealed Nasdaq's determination and presented a Compliance Plan to the Hearings Panel on May 29, 2025.
• On June 9, 2025, the company received a letter from the Hearings Panel stating that its appeal was accepted.
• The company's common stock will resume trading on the Nasdaq Capital Market provided it regains compliance with the Minimum Bid Price Requirement by August 5, 2025.
• The Hearings Panel will maintain jurisdiction over the company until October 20, 2025, requiring notification of any new non-compliance.
• To regain compliance, Spruce Biosciences is seeking stockholder approval at its upcoming 2025 Annual Meeting on July 22, 2025, for a reverse stock split with a ratio between 1-for-50 and 1-for-100.

Sentiment

Score: 6

Explanation: The sentiment is cautiously positive. While the company received a favorable decision from Nasdaq, it still faces the significant challenge of executing a reverse stock split and regaining compliance, with ongoing scrutiny from the Hearings Panel. The situation is improved but not fully resolved.

Positives

• The Nasdaq Hearings Panel accepted Spruce Biosciences' appeal, providing a path to relist on the Nasdaq Capital Market.
• The company has a specific deadline (August 5, 2025) to regain compliance, offering clarity on the required actions.

Negatives

• Spruce Biosciences' common stock was suspended from Nasdaq trading and moved to the OTC Pink Marketplace due to non-compliance with the minimum bid price requirement.
• The company is required to undertake a reverse stock split, which often signals underlying financial challenges and can be dilutive or negatively perceived by investors.
• The Hearings Panel will maintain jurisdiction until October 20, 2025, indicating ongoing scrutiny and potential for further issues if other Nasdaq rules are violated.

Risks

• The company may fail to regain compliance with the Minimum Bid Price Requirement by the August 5, 2025 deadline, leading to permanent delisting from Nasdaq.
• Stockholders may not approve the proposed reverse stock split at the 2025 Annual Meeting, hindering the company's ability to meet the bid price requirement.
• Even if compliance is regained, the company faces the risk of becoming non-compliant with other Nasdaq Listing Rules during the Hearings Panel's jurisdiction period (until October 20, 2025), which would require further action.
• General business risks, geopolitical, and macroeconomic events could impact the company's ability to maintain compliance and its overall operations.

Future Outlook

Spruce Biosciences is diligently working to regain compliance with the Nasdaq Minimum Bid Price Requirement, primarily through a proposed reverse stock split, with the aim of resuming trading on the Nasdaq Capital Market. The company acknowledges that actual results may differ due to various risks and uncertainties.

Management Comments

• "The Company is diligently working to regain compliance with the Minimum Bid Price Requirement, including by seeking stockholder approval, at the Companys upcoming 2025 Annual Meeting of Stockholders on July 22, 2025, to effect a reverse stock split of the Companys common stock with a ratio in the range between and including 1-for-50 and 1-for-100."

Industry Context

For a biotechnology company like Spruce Biosciences, maintaining a Nasdaq listing is crucial for visibility, liquidity, and attracting institutional investment. Delisting to the OTC market can severely impact a company's ability to raise capital and conduct clinical trials, as investor confidence may wane. Regaining a Nasdaq listing is a critical step for biotech firms to access broader capital markets and maintain credibility within the highly competitive pharmaceutical and life sciences industry.

Stakeholder Impact

• Shareholders: The potential for the company to relist on Nasdaq could improve liquidity and investor confidence, but the proposed reverse stock split will reduce the number of outstanding shares and increase the per-share price, which can be perceived negatively by some investors.
• Employees: Maintaining a Nasdaq listing can contribute to company stability and morale, potentially impacting employee retention and recruitment.

Next Steps

• Spruce Biosciences will hold its 2025 Annual Meeting of Stockholders on July 22, 2025, to seek approval for a reverse stock split.
• The company must regain compliance with the Nasdaq Minimum Bid Price Requirement by August 5, 2025.
• The company will be required to advise the Nasdaq Hearings Panel on its plan to cure any listing deficiency should it become non-compliant with any Nasdaq Listing Rule before October 20, 2025.

Key Dates

Recommendation

Keywords

Spruce Biosciences, Nasdaq, Delisting, Minimum Bid Price, Reverse Stock Split, OTC Pink Marketplace, Compliance Plan, SPRB, Biotechnology, SEC Filing